Page 3 - Xlife Sciences News Today

<p class="lead">Despite the adverse market conditions and widespread volatility over the last 12 months, the life sciences sector at SIX Swiss Exchange has proven to be less exposed to volatility and valuation corrections compared to other capital markets. The recent turbulence also reinforces how important it is for companies to think carefully about where they choose to list their businesses.</p>
<div></div>
<div class="fig">&...

The prevalence of amyotrophic lateral sclerosis has been rising over the past few years, which prompts the growing demand for treatment options. The increasing prevalence of amyotrophic lateral

/PRNewswire/ -- DelveInsights Amyotrophic Lateral Sclerosis Pipeline Insight – 2023 report provides comprehensive global coverage of available, marketed,...

Xlife Sciences AG / Key word(s): Miscellaneous/Regulatory Approval16-Feb-2023 / 07:00 CET/CESTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Medical Screening Device Set to Measure Complex Neurocognitive Performance for Early Detection of...

23.01.2023 - Xlife Sciences AG / Key word(s): Miscellaneous Stifel initiates research coverage of Xlife Sciences 23.01.2023 / 07:00 CET/CEST   The renowned investment bank Stifel commenced its research coverage of Xife Sciences (SIX: XLS). The corresponding ...

Xlife Sciences AG / Key word(s): PatentXlife Sciences: Swiss portfolio company Axenoll receives strategically significant patent by the European Patent OfficeTitle 20.01.2023 / 07:00 CET/CESTXlife Sciences AG (SIX: XLS) announced today that its Swiss portfolio company Axenoll Life Sciences AG has been granted a stra...

Xlife Sciences AG / Key word(s): MiscellaneousXlife Sciences portfolio company launches project to research a potential therapy for amyotrophic lateral sclerosis (ALS) 16.01.2023 / 07:00 CET/CESTXlife Sciences' (SIX: XLS) portfolio company inflamed pharma has launched a research project to develop a potential th...

16.01.2023 - Xlife Sciences AG / Key word(s): Miscellaneous Xlife Sciences portfolio company launches project to research a potential therapy for amyotrophic lateral sclerosis (ALS) 16.01.2023 / 07:00 CET/CEST Xlife Sciences (SIX: XLS) portfolio company ... Seite 1

<p><span>In a difficult macroeconomic environment, SIX Swiss Exchange ensured stable trading and efficient capital raising. Trading activity remained close to last year’s levels while the Swiss Market Index SMI® declined by 16.7%. Facilitating capital raising with new offerings, SIX Swiss Exchange recorded fourteen company listings, including its first ever Sparks and nine GDRs listings. In addition, nine new product issuers and six trading participants joined in 20...

Xlife Sciences AG / Key word(s): MiscellaneousPortfolio company Lysatpharma and joint venture Novaxomx start with research and product development in biosurgical treatment therapies 01.12.2022 / 07:01 CET/CESTLysatpharma, a portfolio company of Xlife Sciences (SIX: XLS), and Novaxomx, a joint-venture of Xlife Scienc...